19043 research outputs found
Sort by
Assessing Engagement in Rehabilitation: Development, Validity, Reliability, and Responsiveness to Change of the Rehabilitation Observation Measure of Engagement (ROME)
No full textPURPOSE: We describe the development of an observational video coding tool, the Rehabilitation Observation Measure of Engagement (ROME), to quantify engagement in rehabilitative settings at the person (internal state of an individual) and between-system (interaction between individuals) level. METHODS: Forty-nine children with unilateral spastic cerebral palsy (29 males; Age: = 9.28 yrs, SD = 3.08 yrs) and their interventionists were videotaped during different activities. Construct validity was examined by correlating the ROME with the Engagement vs. Disaffection with Learning Survey and the Pediatric Rehabilitation Intervention Measure of Engagement - Observation questionnaire. Inter- and intra-rater reliability were examined using two independent raters. The ROME\u27s responsiveness to change was examined by comparing scores across activities. RESULTS: For construct validity, results showed a positive correlation for person-level engagement ( = 0.444, = 0.003). No relationship was found between-system-level engagement. High intrarater (91.8%) and interrater (96.1%) reliability was found. The ROME\u27s responsiveness to change was supported by children exhibiting lower engagement scores during repetitive shaping activities. CONCLUSION: These findings provide evidence that the ROME is a reliable tool to objectively examine the construct of engagement within rehabilitation and is valid for quantifying person-level engagement. It provides information that cannot be extracted from questionnaires and can help guide intervention decisions
Single Patch Technique for Aortic Annulus Reconstruction in Prosthetic Valve Endocarditis
No full textAortic root reconstruction during aortic root replacement for a patient with prosthetic valve endocarditis and aortic root abscess can be a difficult procedure with many possible complications. In this video case report, we describe our novel technique using a single bovine pericardial patch that avoids deep stitches or external sutures to support the friable annulus. Compared with more standard methods, this approach has shorter cross-clamp and cardiopulmonary bypass times and is less demanding technically
Pharmacologic Treatment of Schizophrenia Beyond Dopamine Receptor Blockade-Has Its Time Come Yet?
No full textInTouch Week of March 18, 2024
Get PDFMatch Day Marks Another Milestone for Class of 2024 Intersection of Innovation and Health Care Subject of NYMedTalks Study Reveals Concerning Link Between Growth Hormone Therapy and Growth Plate Fractures in Children Students, Staff, and Faculty Pet Their Stress Away LCME Element of the Week Alumni Spotlight: D.P.T. Alumnus Finds Solace in Writing After Cardiac Eventhttps://touroscholar.touro.edu/in_touch/1319/thumbnail.jp
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
No full textINTRODUCTION: ERBB2 amplification in lung cancer remains poorly characterized. HER2 (encoded by ERBB2) is a transmembrane tyrosine kinase capable of ligand-independent dimerization and signaling when overexpressed, and a common cause of HER2 overexpression is ERBB2 amplification. Here, we evaluated the clinicopathologic and genomic characteristics of ERBB2-amplified NSCLC and explored a HER2 antibody-drug conjugate (ADC) therapeutic strategy.
METHODS: Our institutional next-generation DNA sequencing data (OncoPanel) from 5769 NSCLC samples (5075 patients) were queried for cases having high-level ERBB2 amplification (≥6 copies). Clinical and demographic characteristics were extracted from the electronic medical records. Efficacy of the pan-ERBB inhibitor afatinib or HER2 ADCs (trastuzumab deruxtecan and trastuzumab emtansine) was evaluated in NSCLC preclinical models and patients with ERBB2 amplification.
RESULTS: High-level ERBB2 amplification was identified in 0.9% of lung adenocarcinomas and reliably predicted overexpression of HER2. ERBB2 amplification events are detected in two distinct clinicopathologic and genomic subsets of NSCLC: as the sole mitogenic driver in tumors arising in patients with a smoking history or as a concomitant alteration with other mitogenic drivers in patients with a light or never smoking history. We further reveal that trastuzumab deruxtecan is effective therapy in in vitro and in vivo preclinical models of NSCLC harboring ERBB2 amplification and report two cases of clinical activity of an anti-HER2 ADC in patients who acquired ERBB2 amplification after previous targeted therapy.
CONCLUSIONS: High-level ERBB2 amplification reliably predicts HER2 overexpression in patients with NSCLC, and HER2 ADC is effective therapy in this population
